[EN] COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE [FR] COMPOSITIONS ET PROCEDES LES UTILISANT POUR LE TRAITEMENT DE MALADIE NEURODEGENERATIVE ET MITOCHONDRIALE
Convenient and Efficient Syntheses of<i>N</i><sup>6</sup>- and<i>N</i><sup>4</sup>- Substituted Adenines and Cytosines and their 2′-Deoxyribosides
作者:Ewelina Adamska、Jan Barciszewski、Wojciech T. Markiewicz
DOI:10.1080/15257770.2012.742198
日期:2012.12
Convenient and efficient methods of the synthesis of N6- and N4-substituted derivatives of adenine and cytosine and their 2′-deoxyribosides were developed. The reactions of either unprotected nucleobases (adenine, cytosine) or unprotected 2′-deoxyribosides with aryl or alkyl aldehydes give corresponding Schiff bases that can be reduced to the target title compounds with high overall yields. In the
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
申请人:Mitokinin, LLC
公开号:US10167286B2
公开(公告)日:2019-01-01
The disclosure is directed to compounds and pharmaceutically acceptable salts thereof for the treatment and/or prevention of neurodegenerative and/or mitochondrial diseases, such as Parkinson's disease and Leigh's disease. The compounds and pharmaceutically acceptable salts thereof are of the class of nitrogenous bases, for example, pyrimidines, purines, pteridines and pharmaceutically acceptable salts thereof.
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
申请人:The Regents of the University of California
公开号:US10723737B2
公开(公告)日:2020-07-28
Disclosed herein inter alia are compositions and methods useful in the treatment neurodegenerative diseases and cardiomyopathy, and for modulating the activity of PINK1.
本文特别披露了用于治疗神经退行性疾病和心肌病以及调节 PINK1 活性的组合物和方法。
Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
申请人:Mitokinin, Inc.
公开号:US10851109B2
公开(公告)日:2020-12-01
The disclosure is directed to compounds and pharmaceutically acceptable salts thereof for the treatment and/or prevention of neurodegenerative and/or mitochondrial diseases, such as Parkinson's disease and Leigh's disease. The compounds and pharmaceutically acceptable salts thereof are of the class of nitrogenous bases, for example, pyrimidines, purines, pteridines, and pharmaceutically acceptable salts thereof.